{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:11:40Z","timestamp":1790615500339,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute","award":["R01CA17848-01"],"award-info":[{"award-number":["R01CA17848-01"]}]},{"name":"National Institutes of Health\/National Cancer Institute","award":["R21 CA182322"],"award-info":[{"award-number":["R21 CA182322"]}]},{"name":"National Institutes of Health\/National Cancer Institute","award":["U54CA198999"],"award-info":[{"award-number":["U54CA198999"]}]},{"name":"Carolina Center of Cancer Nanotechnology Excellence (CCNE)-Nano Approaches to Modulate Host Cell Response for Cancer Therapy"},{"name":"Carolina Cancer Nanotechnology T32 Training Program","award":["NIH- 1T32CA196589"],"award-info":[{"award-number":["NIH- 1T32CA196589"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.biomaterials.2018.03.055","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T11:26:27Z","timestamp":1522495587000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models"],"prefix":"10.1016","volume":"169","author":[{"given":"Maofan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"IV","given":"C. Tilden","family":"Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuangzeng","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kin Man","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusra","family":"Medik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2018.03.055_bib1","doi-asserted-by":"crossref","DOI":"10.5772\/55562","article-title":"Molecular mechanisms of platinum resistance in ovarian cancer","author":"Tapia","year":"2013","journal-title":"Ovarian Canc. A Clin. Transl. Updat. InTech."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib3","first-page":"186","article-title":"New, expanded, and modified use of approved antineoplastic agents in ovarian cancer","volume":"12","author":"Markman","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib4","first-page":"26","article-title":"Second-line treatment of ovarian cancer","volume":"5","author":"Markman","year":"2000","journal-title":"Oncology"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1758834014544121","article-title":"Treatment options in recurrent ovarian cancer: latest evidence and clinical potential","volume":"6","author":"Luvero","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib6","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1002\/anie.201201562","article-title":"Combating the drug resistance of cisplatin using a platinum prodrug based delivery system","volume":"51","author":"Min","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/pr.111.005637","article-title":"Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes","volume":"64","author":"Shen","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib8","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1172\/JCI115080","article-title":"Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation","volume":"87","author":"Parker","year":"1991","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1269\/jrr.44.151","article-title":"DNA-PK: the major target for wortmannin-mediated radiosensitization by the inhibition of DSB repair via NHEJ pathway","volume":"44","author":"Hashimoto","year":"2003","journal-title":"J.\u00a0Radiat. Res."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2307\/3579783","article-title":"Wortmannin inhibits repair of DNA double-strand breaks in irradiated normal human cells","volume":"149","author":"Okayasu","year":"1998","journal-title":"Radiat. Res."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib12","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1039\/b504418a","article-title":"Chemistry and biology of wortmannin","volume":"3","author":"Wipf","year":"2005","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib13","doi-asserted-by":"crossref","first-page":"8230","DOI":"10.1073\/pnas.1120508109","article-title":"Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery","volume":"109","author":"Karve","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib14","doi-asserted-by":"crossref","first-page":"8976","DOI":"10.1021\/acsnano.5b02913","article-title":"Improving cancer chemoradiotherapy treatment by dual controlled release of wortmannin and docetaxel in polymeric nanoparticles","volume":"9","author":"Au","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2017.03.002","article-title":"Effect of particle size on the biodistribution, toxicity, and efficacy of drug-loaded polymeric nanoparticles in chemoradiotherapy","author":"Caster","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib16","doi-asserted-by":"crossref","first-page":"17939","DOI":"10.1073\/pnas.1011368107","article-title":"Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy","volume":"107","author":"Kolishetti","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib17","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.bcp.2012.01.008","article-title":"Nanoparticle-based combination therapy toward overcoming drug resistance in cancer","volume":"83","author":"Hu","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib18","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.1002\/adfm.201401076","article-title":"Nanoparticles with precise ratiometric Co-Loading and Co-Delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer","volume":"24","author":"Miao","year":"2014","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib19","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4103\/2278-330X.149950","article-title":"Novel formulation of cytarabine and daunorubicin: a new hope in AML treatment","volume":"4","author":"Raut","year":"2015","journal-title":"South Asian J. Canc."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib21","doi-asserted-by":"crossref","first-page":"11147","DOI":"10.1021\/acs.chemrev.5b00116","article-title":"Clinical translation of nanomedicine","volume":"115","author":"Min","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib22","doi-asserted-by":"crossref","first-page":"18638","DOI":"10.1073\/pnas.1303958110","article-title":"Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug","volume":"110","author":"Xu","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib23","doi-asserted-by":"crossref","first-page":"9915","DOI":"10.1021\/ic4010642","article-title":"The effect of ligand lipophilicity on the nanoparticle encapsulation of Pt(IV) prodrugs","volume":"52","author":"Johnstone","year":"2013","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib24","doi-asserted-by":"crossref","first-page":"7732","DOI":"10.1016\/j.biomaterials.2011.06.072","article-title":"Biodegradable polymer\u00a0\u2212 cisplatin(IV) conjugate as a pro-drug of cisplatin(II)","volume":"32","author":"Xiao","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib25","doi-asserted-by":"crossref","first-page":"6507","DOI":"10.1016\/j.biomaterials.2012.05.049","article-title":"A\u00a0prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance","volume":"33","author":"Xiao","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib26","doi-asserted-by":"crossref","first-page":"8657","DOI":"10.1016\/j.biomaterials.2012.08.015","article-title":"The use of polymeric platinum(IV) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy","volume":"33","author":"Xiao","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib27","unstructured":"L.J. Kuo, L.-X. Yang, Gamma-H2AX - a novel biomarker for DNA double-strand breaks., In\u00a0Vivo. 22 (n.d.) 305\u2013309. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18610740."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib28","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"\u03b3H2AX: A sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib30","article-title":"Radiobiology for the radiologist","volume":"224","year":"2002","journal-title":"Radiology"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib31","series-title":"Cisplatin Injection","first-page":"1","author":"FDA","year":"2015"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijpharm.2011.12.043","article-title":"Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration","volume":"424","author":"Semete","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2147\/IJN.S121881","article-title":"Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile","volume":"12","author":"Rafiei","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib34","first-page":"1345","article-title":"Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content","volume":"7","author":"Li","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib35","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.1039\/C7TB01370A","article-title":"Co-delivery of paclitaxel and cisplatin with biocompatible PLGA-PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models","volume":"5","author":"Tian","year":"2017","journal-title":"J.\u00a0Mater. Chem. B"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0168-3659(01)00530-2","article-title":"PLGA\u2013mPEG nanoparticles of cisplatin: in\u00a0vitro nanoparticle degradation, in\u00a0vitro drug release and in\u00a0vivo drug residence in blood properties","volume":"79","author":"Avgoustakis","year":"2002","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/1567201043334605","article-title":"Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery","volume":"1","author":"Avgoustakis","year":"2004","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib38","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib39","doi-asserted-by":"crossref","DOI":"10.4161\/onci.25962","article-title":"Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment","volume":"2","author":"Kershaw","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.biomaterials.2018.03.055_bib40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2141.2007.06524.x","article-title":"Long-term safety of filgrastim (rhG-CSF) administration","volume":"137","author":"Confer","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biomaterials.2018.03.055_bib41","doi-asserted-by":"crossref","first-page":"17356","DOI":"10.1073\/pnas.0809154105","article-title":"Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles","volume":"105","author":"Dhar","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961218302333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961218302333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:32:35Z","timestamp":1758904355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961218302333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":41,"alternative-id":["S0142961218302333"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2018.03.055","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2018.03.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}